Ikena Oncology Inc (IKNA) - Total Liabilities
Based on the latest financial reports, Ikena Oncology Inc (IKNA) has total liabilities worth $10.26 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Ikena Oncology Inc to assess how effectively this company generates cash.
Ikena Oncology Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's total liabilities have evolved over time, based on quarterly financial data. Check Ikena Oncology Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Ikena Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Ikena Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
A-Tech Solution Co. Ltd
KQ:071670
|
Korea | ₩221.67 Billion |
|
JKG Land Bhd
KLSE:6769
|
Malaysia | RM256.78 Million |
|
Luo Lih Fen Holding Co Ltd
TW:6666
|
Taiwan | NT$581.03 Million |
|
Titania Holding AB Series B
ST:TITA-B
|
Sweden | Skr3.70 Billion |
|
Infragreen Group Ltd
AU:IFN
|
Australia | AU$8.31 Million |
|
Professional Computer Technology Ltd
TWO:6270
|
Taiwan | NT$1.19 Billion |
|
Taiwan Ostor
TWO:8080
|
Taiwan | NT$469.81 Million |
|
Kuangli Photoelectric Technology Co Ltd
TW:6431
|
Taiwan | NT$538.70 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Ikena Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Ikena Oncology Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ikena Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ikena Oncology Inc (2018–2024)
The table below shows the annual total liabilities of Ikena Oncology Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $15.58 Million | -30.26% |
| 2023-12-31 | $22.34 Million | -11.68% |
| 2022-12-31 | $25.29 Million | -36.78% |
| 2021-12-31 | $40.00 Million | -85.15% |
| 2020-12-31 | $269.45 Million | +82.76% |
| 2019-12-31 | $147.44 Million | +121.66% |
| 2018-12-31 | $66.52 Million | -- |
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more